Literature DB >> 16905213

Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.

Esther G C Troost1, Peter Laverman, Johannes H A M Kaanders, Mariëlle Philippens, Jasper Lok, Wim J G Oyen, Albert J van der Kogel, Otto C Boerman, Johan Bussink.   

Abstract

PURPOSE: Hypoxia is one of the reasons for radiation therapy resistance. Positron emission tomography using (18)F-labeled misonidazole ([(18)F]FMISO) is a non-invasive method of imaging tumor hypoxia. Aim of this study was to validate [(18)F]FMISO against the clinically most widely used hypoxic cell marker pimonidazole under different oxygenation conditions.
MATERIALS AND METHODS: One human head and neck squamous cell carcinoma (SCCNij3) and two human glioblastoma (E102 and E106) xenograft tumor lines were studied after injection of [(18)F]FMISO and pimonidazole. Control mice were compared with a second group breathing carbogen to reduce tumor hypoxia and with a third group with clamped tumors to increase hypoxia. Tumor sections were analyzed on a phosphor imaging system and consecutively stained immunohistochemically (IHC) for visualization of pimonidazole. Pixel-by-pixel analysis was performed and the hypoxic fraction, obtained after segmentation of the pimonidazole signal, was related to the mean optical density of [(18)F]FMISO and pimonidazole.
RESULTS: A moderate pixel-by-pixel correlation between [(18)F]FMISO autoradiography and pimonidazole IHC was found for the control tumors, after carbogen breathing and after clamping for SCCNij3. For E102 and E106, mean signal intensities for pimonidazole significantly decreased after carbogen breathing and increased after clamping, mean [(18)F]FMISO signal intensities increased significantly after clamping and a significant correlation between the hypoxic fractions and the mean [(18)F]FMISO signal intensities was found.
CONCLUSIONS: [(18)F]FMISO autoradiography and pimonidazole immunohistochemistry can both be used to visualize treatment induced changes in tumor hypoxia. However, the response to these modifications differs widely between xenograft tumor lines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905213     DOI: 10.1016/j.radonc.2006.07.023

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

1.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.

Authors:  Satish K Chitneni; Gerald T Bida; Michael R Zalutsky; Mark W Dewhirst
Journal:  J Nucl Med       Date:  2014-05-22       Impact factor: 10.057

Review 3.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

Review 4.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 5.  Brain tumors.

Authors:  Karl Herholz; Karl-Josef Langen; Christiaan Schiepers; James M Mountz
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

Review 6.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 7.  Molecular imaging of hypoxia with radiolabelled agents.

Authors:  Gilles Mees; Rudi Dierckx; Christel Vangestel; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-30       Impact factor: 9.236

Review 8.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

10.  Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.

Authors:  Esther G C Troost; Peter Laverman; Mariëlle E P Philippens; Jasper Lok; Albert J van der Kogel; Wim J G Oyen; Otto C Boerman; Johannes H A M Kaanders; Johan Bussink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.